H020 Chronic expression of osteopontin in cardiomyocytes led to dilated cardiomyopathy  by Renault, M.-A. et al.
Abstracts S79
H020
CHRONIC EXPRESSION OF OSTEOPONTIN 
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Osteopontin (OPN) is not expressed in healthy heart while, its 
expression is dramatically increased in cardiomyocytes and 
in ammatory cells during cardiomyopathies and heart failure. 
However its role in the development of heart diseases is not known.
To understand whether OPN is involved in cardiomyopathy, we 
created a transgenic mouse (MHC-OPN) expressing recombinant OPN 
(rOPN) speci cally in cardiomyocytes using aMHC promoter-directed 
OPN expression and tTA technology. In these mice, rOPN expression 
could be regulated by doxycyclin oral administration.
After birth, MHC-OPN young mice were phenotypically 
indistinguishable from their littermate controls, but most of them 
died early between the 8 th and 15 th weeks after birth with a half 
life of 12 weeks. However, less than 10 % MHC-OPN mice survived 
and were still alive 30 weeks after birth. Inhibition of recombinant 
OPN expression by doxycyclin at the beginning of T cell in ltration (5 
weeks after birth) or when DCM was initiated (11 weeks after birth) 
reduced myocarditis and thus avoided the early death.
Electrocardiography demonstrated atrio-ventricular and intra 
ventricular defects. Moreover, echocardiography showed left 
ventricular dilation without hypertrophy and a systolic dysfunction, 
as indicated by reduced left ventricular fractional shortening (control 
mice: 29,8±2,0 %, n=13 ; and MHC-OPN mice: 13,7±4,0 %, n=5 ; T test 
p<0.05). In vitro histology con rmed that mice died because of a 
dilated cardiomyopathy associated with a strong  brosis.
By immunohistology, we demonstrated that OPN expression in 
cardiomyocytes induced an important cell in ltration including some 
macrophages and a large number of  broblasts and activated CD4+ 
and CD8+ T cells.
All together these experiments suggested that chronic OPN expression 
is required for DCM development inducing Tcell activation and thus a 
chronic myocarditis resulting in the dilated cardiomyopathy.
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We have shown previously that chronic, in vivo pharmacological 
inhibition of protein tyrosine phosphatase 1B (PTP1B) prevented 
both endothelial and cardiac dysfunction in mice with chronic 
heart failure (CHF). The present study was designed to test 
whether similar cardiovascular protective effects are present in 
mice genetically de cient for PTP1B.
CHF was induced by coronary ligation, either in wild type (WT) 
or PTP1B de cient (PTP1B-/-) BALB/c mice. After 2 months of 
ligation, echocardiographic analysis of left ventricular (LV) function 
and remodelling was performed, after which  ow-mediated, NO-
dependent vasodilatation (FMD) of mesenteric resistance arteries 
was evaluated.
In PTP1B-/- mice with CHF (n=13), compared to CHF WT mice (n=15) 
LV end diastolic diameter (LVEDD) and LV end systolic diameter (LVESD) 
were reduced (LVEDD: CHF WT 6.1±0.2 ; CHF PTP1B-/- 5.2±0.2 mm, 
p<0.01 ; LVESD: CHF WT 5.5±0.2 ; CHF PTP1B-/- 3.9±0.3 mm, p<0.01), 
while fractional shortening (FS) and cardiac output (CO) were increased 
(FS: CHF WT 10.9±1.6 ; CHF PTP1B-/- 22.7±2.5 %, p<0.01 ; CO: WT 
16.3±1.0 ; PTP1B-/- 22.2±1.1 ml/min, p<0.05). Genetic disruption of 
PTP1B was also associated with decreased collagen density. These 
hemodynamic and structural effects were observed in the context of 
identical infarct sizes.
Vascular studies showed that compared to CHF WT mice (n=15), CHF 
PTP1B-/- mice (n=16) displayed an increased FMD (CHF WT 5±1, 
CHF PTP1B-/- 19±4 %, p<0.05). Additionally, in vitro downregulation 
of PTP1B (by a 3 day incubation with shRNA) also increased FMD in 
arteries isolated from CHF mice (max FMD ; untreated: 6±2 ; scrambled 
shRNA: 7±2 ; PTP1B shRNA 27±2 %, p<0.01).
Thus, genetic disruption of PTP1B prevent endothelial and cardiac 
dysfunction in CHF mice, suggesting that this enzyme may be a new 
interesting target for the treatment of CHF.
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Alterations in RyR2 function is a hallmark of heart failure (HF). 
Decreased FKBP12.6 binding to RyR2 has been put forward to explain 
the diastolic SR Ca2+ leakage observed in this condition. Previous 
work in the mouse has shown that cardiac FKBP12.6 overexpression 
protects against the development of myocardial infarction-induced 
heart failure. Using a mouse model of conditional cardiac-speci c 
FKBP12.6 overexpression, we tested the hypothesis that this 
overexpression protects against transverse aortic constriction 
(TAC)-induced cardiac remodelling and failure.
Ten weeks after TAC, male transgenic (DT) and their littermates 
controls (Ctr) underwent heart catheterization. Ventricular 
expression of the hypertrophic gene program and calcium handling 
proteins were assessed by real-time PCR and Western blot, 
respectively.Ten weeks after TAC, the mortality rate was 23 % in 
Ctr and 13 % in DT (14/60 vs 5/39, ns). The percentage of mice with 
